Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
- Published in:
- Clinical Pharmacology, 2022, v. 14, p. 49, doi. 10.2147/CPAA.S345072
- By:
- Publication type:
- Article
Works by Genao, Edilberto Peña
Results: 4
1
2
Safety and Tolerability of PCSK9 Inhibitors: Current Insights.
- Published in:
- Clinical Pharmacology, 2020, v. 12, p. 191, doi. 10.2147/CPAA.S288831
- By:
- Publication type:
- Article
3
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.
- Published in:
- Therapeutics & Clinical Risk Management, 2020, v. 16, p. 1031, doi. 10.2147/TCRM.S230592
- By:
- Publication type:
- Article
4
The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease.
- Published in:
- Diagnostics (2075-4418), 2023, v. 13, n. 5, p. 929, doi. 10.3390/diagnostics13050929
- By:
- Publication type:
- Article